Larimar Therapeutics (LRMR) Competitors $1.93 -0.13 (-6.31%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.02 +0.09 (+4.46%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. GHRS, STOK, KURA, OPT, URGN, UPB, MNMD, DNA, ARVN, and TSHAShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include GH Research (GHRS), Stoke Therapeutics (STOK), Kura Oncology (KURA), Opthea (OPT), UroGen Pharma (URGN), Upstream Bio (UPB), Mind Medicine (MindMed) (MNMD), Ginkgo Bioworks (DNA), Arvinas (ARVN), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. GH Research Stoke Therapeutics Kura Oncology Opthea UroGen Pharma Upstream Bio Mind Medicine (MindMed) Ginkgo Bioworks Arvinas Taysha Gene Therapies Larimar Therapeutics (NASDAQ:LRMR) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability. Does the media refer more to LRMR or GHRS? In the previous week, GH Research had 4 more articles in the media than Larimar Therapeutics. MarketBeat recorded 7 mentions for GH Research and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.27 beat GH Research's score of 0.23 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, LRMR or GHRS? Larimar Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Is LRMR or GHRS more profitable? GH Research's return on equity of -20.29% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -35.87% -32.37% GH Research N/A -20.29%-19.49% Which has better valuation & earnings, LRMR or GHRS? GH Research is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$36.95M-$1.49-1.30GH ResearchN/AN/A-$35.59M-$0.79-14.92 Do institutionals & insiders hold more shares of LRMR or GHRS? 91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 41.6% of GH Research shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend LRMR or GHRS? Larimar Therapeutics presently has a consensus target price of $20.43, suggesting a potential upside of 958.48%. GH Research has a consensus target price of $30.43, suggesting a potential upside of 158.09%. Given Larimar Therapeutics' higher possible upside, equities analysts plainly believe Larimar Therapeutics is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10GH Research 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the MarketBeat Community favor LRMR or GHRS? Larimar Therapeutics received 13 more outperform votes than GH Research when rated by MarketBeat users. However, 78.57% of users gave GH Research an outperform vote while only 71.88% of users gave Larimar Therapeutics an outperform vote. CompanyUnderperformOutperformLarimar TherapeuticsOutperform Votes4671.88% Underperform Votes1828.13% GH ResearchOutperform Votes3378.57% Underperform Votes921.43% SummaryGH Research beats Larimar Therapeutics on 8 of the 15 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$123.57M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-1.688.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book1.046.466.794.50Net Income-$36.95M$143.98M$3.23B$248.18M7 Day Performance3.21%2.03%1.53%0.20%1 Month Performance-18.91%4.11%10.06%12.37%1 Year Performance-75.57%-2.87%16.72%7.04% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics2.0664 of 5 stars$1.93-6.3%$20.43+958.5%-75.5%$123.57MN/A-1.6830GHRSGH Research2.5349 of 5 stars$10.16-2.1%$30.43+199.5%-4.6%$528.60MN/A-12.8610STOKStoke Therapeutics3.4811 of 5 stars$9.66+3.2%$25.60+165.0%-38.2%$527.41M$36.56M-4.60100Positive NewsAnalyst RevisionGap UpKURAKura Oncology4.3081 of 5 stars$6.09+5.7%$23.89+292.3%-72.0%$527.24M$67.99M-2.58130Positive NewsAnalyst ForecastAnalyst RevisionOPTOpthea0.671 of 5 stars$3.41+7.2%$1.33-60.9%+1.8%$524.84M$87,666.000.008Gap UpURGNUroGen Pharma4.0691 of 5 stars$11.14+7.3%$32.86+194.9%-68.6%$513.63M$90.40M-3.54200Trending NewsGap DownUPBUpstream Bio2.0909 of 5 stars$9.50+7.7%$56.50+494.7%N/A$511.04M$2.30M0.0038News CoverageMNMDMind Medicine (MindMed)2.2672 of 5 stars$6.45+4.9%$25.11+289.3%-16.8%$486.12MN/A-2.8540Positive NewsDNAGinkgo Bioworks1.1157 of 5 stars$8.30+6.9%$4.58-44.9%N/A$481.62M$237.42M-0.63640Positive NewsARVNArvinas3.7265 of 5 stars$6.52-1.4%$20.91+220.7%-82.0%$475.90M$426.90M-2.35420TSHATaysha Gene Therapies3.0123 of 5 stars$2.32+8.9%$6.63+185.6%+0.0%$475.73M$8.33M3.68180Earnings ReportAnalyst RevisionGap Down Related Companies and Tools Related Companies GH Research Alternatives Stoke Therapeutics Alternatives Kura Oncology Alternatives Opthea Alternatives UroGen Pharma Alternatives Upstream Bio Alternatives Mind Medicine (MindMed) Alternatives Ginkgo Bioworks Alternatives Arvinas Alternatives Taysha Gene Therapies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LRMR Stock Free LRMR Stock Alerts